Kineret Mazor-Aronovitch

Kineret Mazor-Aronovitch

Auto-generated profile, based on publicly available information

Kineret Mazor-Aronovitch

Gray School of Medicine, Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; Pediatric Endocrine and Diabetes Unit, The Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Ramat-Gan, Israel

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2007 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
KMK Mazor-Aronovitch
K Mazor-Aronovitch
DGD Gillis
D Gillis
DLD Lobel
D Lobel
HHH J Hirsch
H J Hirsch
OPO Pinhas-Hamiel
O Pinhas-Hamiel
HLH Landau
H Landau
Background: Congenital hyperinsulinism (CH) is treated surgically in many centers (near-total and partial pancreatectomy for diffuse and focal disease respectively). Most patients treated with near-total pancreatectomy developed diabetes during childhood/puberty. CH patients are at increased risk of neurodevelopmental disorders, some being severe, which are reported to occur in 14–44% of patients from highly heterogenous cohorts. Over the last few decades, we have treated children with CH conservatively without surgery. The aim of this study was to assess the neurodevelopmental outcome of these patients. Design and methods: The study included 21 Ashkenazi CH medically treated patients: 11 homozygotes (diffuse disease) and 9 heterozygotes with mutations on the paternal allele (presumed focal disease). The mean age was 13.7 years (range 8–23). Neurodevelopmental outcomes were assessed by telephone interviews of parents, using a standard questionnaire. Closest age siblings of CH patients served as controls. Results: Ten CH patients had perinatal seizures of short duration. Four had post-neonatal seizures, which remitted entirely. During early childhood, four patients (19%) had hypotonia, eight (38%) had fine motor problems, seven (33%) had gross motor problems (clumsiness), and one had mild cerebral palsy. Three patients (14%) had speech problems. Eight patients required developmental therapy, compared to one in the control group. Most of these problems were resolved by age 4–5 years. At school age, all were enrolled in regular education, some excelled in their studies, 6 out of 21 patients (29%) had learning problems (2 out of 21 controls). None had overt diabetes. Conclusions: Good neurodevelopmental outcome was observed in our conservatively treated CH patients, with no diabetes as reported in patients undergoing pancreatectomy.

1 June 2022 in Pediatric Diabetes
Verified
Journal Article
Closed access
NLNehama Zuckerman Levin
Nehama Zuckerman Levin
MCMeidan Cohen
Meidan Cohen
MPMoshe Phillip
Moshe Phillip
ATAriel Tenenbaum
Ariel Tenenbaum
IKIlana Koren
Ilana Koren
NSNaim Shehadeh
Naim Shehadeh

23 August 2023 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
MRMarianna Rachmiel
Marianna Rachmiel
YLYael Lebenthal
Yael Lebenthal
KMKineret Mazor-Aronovitch
Kineret Mazor-Aronovitch
ABAvivit Brener
Avivit Brener
NLNoah levek
Noah levek
OPOrit Pinhas-Hamiel
Orit Pinhas-Hamiel
Background and Aims: Achieving good glycemic control is a major challenge for adolescents with type 1 diabetes (TID). The introduction of the MiniMed 780G system, an advanced hybrid closed-loop (AHCL) that enables an automatic correction of insulin, gave hope for improved glycemic outcomes in adolescents. We assessed specific characteristics associated with glycemic measures in youth with T1D switching to Minimed 780G. Methods: This retrospective observational real-life multicenter study from the AWeSoMe Group assessed continuous glucose monitoring (CGM) metrics of 22 patients (59% females, median age 13.9 interquartile range [IQR 11,18] years), from a high socioeconomic background. CGM metrics were recorded for 2-week periods before AHCL, after 1, 3, 6 months, and at the end of follow-up (median 10.9 [IQR 5.4, 17.4] months). Delta-variables (Δ) were calculated as the difference between the end of follow-up and baseline. Results: Time in range (TIR) 70–180mg/dL increased from 65% [52, 72] to 75% [63, 80], P = 0.008, from baseline to end of follow-up. Time above range >180mg/dL decreased from 28% [20, 46] to 22% [14, 35], P = 0.047. Advanced pubertal stage was correlated with less improvement in ΔTAR >180mg/dL , r = 0.47, P = 0.05, and less CGM usage r = −0.57, P = 0.05. A longer disease duration was associated with less improvement in ΔTAR 180–250mg/dL , r = 0.48, P = 0.05. Lower pump site change frequency was associated with higher glucose management indicator, r = 0.5, P = 0.03, and lower TIR 70–180mg/dL r = −0.52, P = 0.08. Conclusion: The use of AHCL enabled improvements in TIR 70–180mg/dL in youth with T1D. More advanced pubertal stages, longer disease duration, and less compliance were associated with less improvement, stressing the need for continuous support, and re-education in this age group.

2 March 2021 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
KMKineret Mazor‐Aronovitch
Kineret Mazor‐Aronovitch
OPOrit Pinhas‐Hamiel
Orit Pinhas‐Hamiel
DPDikla Pivko‐Levy
Dikla Pivko‐Levy
DMDalit Modan‐Moses
Dalit Modan‐Moses
NLNoah levek
Noah levek
ZLZohar Landau
Zohar Landau

8 November 2024 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
NGNoah Gruber
Noah Gruber
AWAvigail Wittenberg
Avigail Wittenberg
ABAvivit Brener
Avivit Brener
SAShirli Abiri
Shirli Abiri
KMKineret Mazor-Aronovitch
Kineret Mazor-Aronovitch
YLYael Lebenthal
Yael Lebenthal
Background: We assessed real-life glycemic outcomes and predictors of composite measures of optimal glycemic control in children and adolescents with type 1 diabetes (T1D) during their initial 12 months of the MiniMed™ 780G use. Methods: This prospective observational multicenter study collected demographic, clinical, and 2-week 780G system data at five time points. Optimal glycemic control was defined as a composite glycemic control (CGC) score requiring the attainment of four recommended continuous glucose monitoring (CGM) targets, as well as the glycemia risk index (GRI) of hypoglycemia and hyperglycemia and composite CGM index (COGI). Outcome measures included longitudinal changes in multiple glycemic parameters and CGC, GRI, and COGI scores, as well as predictors of these optimal measures. Results: The cohort included 93 children, 43% girls, with a median age of 15.1 years (interquartile range [IQR] 12.9,17.0). A longitudinal analysis adjusted for age and socioeconomic index yielded a significant improvement in glycemic control for the entire cohort ( p time < 0.001) after the transition to 780G. The mean hemoglobin A1c (HbA1c) (SE) was 8.65% (0.12) at baseline and dropped by >1% after 1 year to 7.54% (0.14) ( p time < 0.001). Optimal glycemic control measures improved at 12 months post 780G; CGC improved by 5.6-fold ( P < 0.001) and was attained by 24% of the participants, the GRI score improved by 10-fold ( P = 0.009) and was achieved by 10% of them, and the COGI improved by 7.6-fold ( P < 0.001) and was attained by 20% of them. Lower baseline HbA1c levels and increased adherence to Advanced Hybrid Closed-Loop (AHCL) usage were predictors of achieving optimal glycemic control. Conclusions: The AHCL 780G system enhances glycemic control in children and adolescents with T1D, demonstrating improvements in HbA1c and CGM metrics, albeit most participants did not achieve optimal glycemic control. This highlights yet ongoing challenges in diabetes management, emphasizing the need for continued proactive efforts on the part of health care professionals, youth, and caregivers.

16 October 2023 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
NGNoah Gruber
Noah Gruber
MSMoran Shemesh-Iron
Moran Shemesh-Iron
EKEthel Kraft
Ethel Kraft
KMKaren Mitelberg
Karen Mitelberg
EMElinor Mauda
Elinor Mauda
OPOrit Pinhas-Hamiel
Orit Pinhas-Hamiel